The U.S. Food and Drug Administration granted Emergency Use Authorization to a combination of Eli Lilly’s and Incyte’s rheumatoid arthritis drug Olumiant (baricitinib) and Gilead Sciences’ remdesivir as a treatment for hospitalized patients diagnosed with Covid-19 who require supplemental oxygen or ventilation.
With all the expectations for available Covid-19 vaccines based on the successful late-stage trial results reported by Pfizer/BioNTech and Moderna, the looming question is: when will the public be able to start getting the vaccines?
Researchers at Weill Cornell Medicine identified a specific and unique kind of immune cell activity in the lungs of Covid-19 patients that is different from the type of immune cell activity found in other respiratory infections.
Results of Viking Therapeutics’ metabolic disease program exceed all other oral therapies in development in terms of reducing liver fat for nonalcoholic steatohepatitis (NASH) patients, according to Greg Zante, the company’s SVP of finance.
AstraZeneca and the University of Oxford published Phase II clinical trial results for their Covid-19 vaccine in The Lancet, with data showing the vaccine is safe and offers a similar immune response in all adults.
Roche’s Actemra helped the sickest Covid-19 patients in a 303-patient study, the trial’s lead investigator said, bolstering what has been mixed evidence that the arthritis drug can be repurposed to help in the pandemic.
Russia resumed the vaccination of new volunteers in a clinical trial for the country’s flagship Covid-19 Sputnik V vaccine after a short pause, staff at six of 29 trial clinics said, as Moscow moves to accelerate plans to inoculate the population.
Topline results from Gilead Sciences’ Phase II/III CAPELLA trial show that treatment with the company’s long-acting HIV-1 capsid inhibitor lenacapavir reduces HIV viral load better than placebo in heavily treated patients living with multidrug resistant HIV-1 infection.
U.S. and European regulators could approve Pfizer and BioNTech’s experimental Covid-19 vaccine as early as mid-December, the German firm’s chief executive said, following the release of positive trial results.
The U.S. Food and Drug Administration granted various designations for Sanofi’s avalglucosidase alfa for Pompe disease, Sanofi’s rilzabrutinib for immune thrombocytopenia, and ViiV Healthcare’s cabotegravir for HIV prevention.